FDA
-
-
-
-
-
-
-
Genmab 2018 Annual Report
-
-
-
-
-
-
-
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma
-
-
-
-
-
-
-
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
-
-
-
-
-
-
-
Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
-
-
-
-
-
-
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017
-
-
-
-
-
-
-
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

